西格列汀联合贝那普利对糖尿病肾病患者糖代谢、肾功能、炎症因子指标的影响

Effects of sitagliptin combined with benazepril on glucose metabolism,renal function and inflammatory factors indexes in patients with diabetic kidney disease

目的观察西格列汀联合贝那普利对糖尿病肾病(DKD)患者糖代谢、肾功能、炎症因子指标的影响。方法随机选取本院2019年1月至2020年12月收治的94例DKD患者,按奇偶数字表法将其分为对照组和观察组,各47例。对照组在常规治疗基础上给予贝那普利治疗,观察组在对照组基础上联合西格列汀治疗。比较两组的糖代谢、肾功能、炎症因子指标及生活质量。结果治疗后,两组FPG、FINS、Scr、NGAL、RBP、β2-MG、IL-6、IL-1β、TNF-α、MCP-1水平、HbA1c、HOMA-IR及DSQL评分均降低,且观察组低于对照组(P<0.05)。结论采用西格列汀联合贝那普利治疗DKD患者,可改善其糖代谢、肾功能、炎症因子指标,提高生活质量,值得推广应用。

Objective To observe the effects of sitagliptin combined with benazepril on glucose metabolism,renal function and inflammatory factors indexes in patients with diabetic kidney disease(DKD).Methods A total of 94 patients with DKD treated in our hospital from January 2019 to December 2020 were randomly selected and divided into control group and observation group according to odd-even number table method,with 47 cases in each group.The control group was treated with benazepril on the basis of routine treatment,and the observation group was combined with sitagliptin treatment on the basis of the control group.The glucose metabolism,renal function,inflammatory factors indexes and quality of life were compared between the two groups.Results After treatment,the FPG,FINS,Scr,NGAL,RBP,β2-MG,IL-6,IL-1β,TNF-α,MCP-1 levels,HbA1c,HOMA-IR and DSQL score in the two groups decreased,and those in the observation group were lower than the control group(P<0.05).Conclusion Sitagliptin combined with benazepril in the treatment of DKD patients can ameliorate glucose metabolism,renal function and inflammatory factors indexes,and improve the quality of life,which is worthy of popularization and application.